Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised Euro12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept

Stock Information for Scinai Immunotherapeutics Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Scinai Immunotherapeutics Ltd.

Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026
Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price
Scinai Announces Expanded Israel Innovation Authority Support for Robotic Aseptic Fill & Finish Platform
Scinai Announces Completion of Acquisition of Recipharm Israel Ltd. and Strategic Commercial Collaboration with Recipharm
Scinai CEO Amir Reichman to Co-Lead Manufacturers Association Biopharma Manufacturing Roundtable at HealthIL
Scinai Reports Nine-Month 2025 Results as CDMO Growth Continues and NanoAbs Pipeline Advances
Scinai Awarded Israel Innovation Authority Grant to Expand Fill-and-Finish CDMO Capabilities
Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.